Exporter

EN
FR
Efavirenz + emtricitabine + tenofovir
Statut de médicament essentiel
Section:
6. Anti-infective medicines 6.4. Antiviral medicines 6.4.2. Antiretrovirals 6.4.2.5. Fixed-dose combinations of antiretrovirals
Codes ATC: J05AR06
Indication
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Code ICD11: 1C62.Z
INN
Efavirenz + emtricitabine + tenofovir
Type de médicament
Chemical agent
Type de liste
Liste de base
Formulations
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
Historique des statuts LME
Ajouté pour la première fois en 2007 (TRS 946)
Modifié en 2021 (TRS 1035)
Sexe
Tous
Âge
Adolescents et adultes
Équivalence thérapeutique
efavirenz + lamivudine + tenofovir (Codes ATC: J05AR11)
Renseignements sur le brevet
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Lire la suite sur les brevets.
Wikipédia
Efavirenz + emtricitabine + tenofovir
DrugBank
Efavirenz ,
Emtricitabine ,
Tenofovir disoproxil
Résumé des preuves et recommandation du comité d'experts
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified a as therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.